Page last updated: 2024-11-07

daq

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID97456
CHEMBL ID4209671
SCHEMBL ID1886441
MeSH IDM0088762

Synonyms (33)

Synonym
AKOS015838412
nsc-124509
2,1-dimethylpropyl)-2,5-cyclohexadiene-1,4-dione
p-benzoquinone,5-di-tert-pentyl-
DAQ ,
2,4-dione, 2,5-bis(1,1-dimethylpropyl)-
2,5-di-tert-amylquinone
4584-63-8
nsc124509
2,5-bis(2-methylbutan-2-yl)cyclohexa-2,5-diene-1,4-dione
D2152
2,5-di-tert-pentyl-1,4-benzoquinone
2,5-di-tert-amylbenzoquinone
SCHEMBL1886441
2,5-di-t-amyl-p-benzoquinone
2,5-bis(1,1-dimethylpropyl)-2,5-cyclohexadiene-1,4-dione
2,5-cyclohexadiene-1,4-dione, 2,5-bis(1,1-dimethylpropyl)-
2,5-di-tert-pentyl-p-benzoquinone
nsc 124509
p-benzoquinone, 2,5-di-tert-pentyl-
2,5-di-tert-pentylcyclohexa-2,5-diene-1,4-dione
DHXFOYLEDAOQRR-UHFFFAOYSA-N
2,5-ditert-pentylbenzo-1,4-quinone #
DTXSID90196628
mfcd00142843
AS-67355
2,5-bis-(1,1-dimethyl-propyl)-(1,4)benzoquinone
2,5-di-t-pentyl-1,4-benzoquinone
FT-0743166
T70938
CHEMBL4209671
A872328
CS-0186514
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1374920Growth inhibition of human A2780cis cells after 72 hrs by SRB assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
The synthesis and evaluation of thymoquinone analogues as anti-ovarian cancer and antimalarial agents.
AID1374922Antiplasmodial activity against Plasmodium falciparum Dd2 by SYBR Green I fluorescence assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
The synthesis and evaluation of thymoquinone analogues as anti-ovarian cancer and antimalarial agents.
AID1374928Growth inhibition of SV-40 immortalized human ovarian epithelial cells after 72 hrs by SRB assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
The synthesis and evaluation of thymoquinone analogues as anti-ovarian cancer and antimalarial agents.
AID1374921Selectivity index, ratio of IC50 for SV-40 immortalized human ovarian epithelial cells to IC50 for human A2780cis cells2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
The synthesis and evaluation of thymoquinone analogues as anti-ovarian cancer and antimalarial agents.
AID1374919Growth inhibition of human OVCAR8 cells after 72 hrs by SRB assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
The synthesis and evaluation of thymoquinone analogues as anti-ovarian cancer and antimalarial agents.
AID1374918Growth inhibition of human A2780 cells after 72 hrs by SRB assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
The synthesis and evaluation of thymoquinone analogues as anti-ovarian cancer and antimalarial agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.14)18.7374
1990's0 (0.00)18.2507
2000's2 (14.29)29.6817
2010's2 (14.29)24.3611
2020's9 (64.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 73.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index73.75 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index5.37 (4.65)
Search Engine Demand Index169.23 (26.88)
Search Engine Supply Index2.80 (0.95)

This Compound (73.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]